Skip to main content
Print Save

Exparel FDA Approval History

FDA Approved: Yes (First approved October 28, 2011)
Brand name: Exparel
Generic name: bupivacaine liposome
Dosage form: Injectable Suspension
Company: Pacira Pharmaceuticals, Inc.
Treatment for: Pain

Exparel (bupivacaine liposome injectable suspension) is a long-acting non-opioid local analgesic for postsurgical local analgesia, and for use as a nerve block (interscalene brachial plexus block) to provide pain relief following shoulder surgeries.

Development timeline for Exparel

DateArticle
Apr  6, 2018Approval Pacira Announces FDA Approval of Exparel as a Nerve Block to Produce Regional Analgesia
Oct 31, 2011Approval Pacira Pharmaceuticals, Inc. Announces U.S. FDA Approval of Exparel For Postsurgical Pain Management
Jun 14, 2011Pacira Pharmaceuticals, Inc. Announces FDA Extension of Exparel PDUFA Target Date By Three Months
Dec 14, 2010Pacira Pharmaceuticals Announces FDA Acceptance of Exparel New Drug Application for Pain Management

See also

Exparel (bupivacaine liposome) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer